相似文献
1
Racial and ethnic disparities in hematologic malignancies.
Blood. 2017 Oct 12;130(15):1699-1705. doi: 10.1182/blood-2017-04-778225. Epub 2017 Jul 19.
2
Lessons to inform interventions to reduce racial and ethnic health disparities within hematologic malignancies.
Cancer Causes Control. 2023 Oct;34(10):883-886. doi: 10.1007/s10552-023-01730-x. Epub 2023 Jun 7.
3
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers.
Lancet Haematol. 2021 Dec;8(12):e947-e954. doi: 10.1016/S2352-3026(21)00303-3.
4
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.
Blood Rev. 2021 May;47:100775. doi: 10.1016/j.blre.2020.100775. Epub 2020 Nov 9.
5
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Biol Blood Marrow Transplant. 2011 Jul;17(7):1025-32. doi: 10.1016/j.bbmt.2010.10.030. Epub 2010 Nov 1.
6
Lean Into the Uncomfortable: Using Trauma-Informed Care to Engage in Shared Decision-Making With Racial Minorities With Hematologic Malignancies.
Am J Hosp Palliat Care. 2022 Jan;39(1):4-8. doi: 10.1177/10499091211008431. Epub 2021 Apr 29.
7
Hematopoietic stem cell transplantation in hematologic malignancy.
Panminerva Med. 2004 Mar;46(1):61-74.
8
Racial/Ethnic Health Disparities Among Rural Adults - United States, 2012-2015.
MMWR Surveill Summ. 2017 Nov 17;66(23):1-9. doi: 10.15585/mmwr.ss6623a1.
9
Racial/Ethnic Health Disparities Among Rural Adults-United States, 2012-2015: / November 17, 2017 / 66(23);1-9.
J Health Care Poor Underserved. 2018;29(1):19-34. doi: 10.1353/hpu.2018.0003.
10
Coverage and framing of racial and ethnic health disparities in US newspapers, 1996-2005.
Am J Public Health. 2010 Apr 1;100 Suppl 1(Suppl 1):S224-31. doi: 10.2105/AJPH.2009.171678. Epub 2010 Feb 10.
引用本文的文献
1
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02693-0.
2
Global, regional, and national burden of leukemia: Epidemiological trends analysis from 1990 to 2021.
PLoS One. 2025 Jun 26;20(6):e0325937. doi: 10.1371/journal.pone.0325937. eCollection 2025.
3
Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf180.
4
Optimal GVHD Prophylaxis.
Adv Exp Med Biol. 2025;1475:77-102. doi: 10.1007/978-3-031-84988-6_5.
5
Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis.
Blood Neoplasia. 2025 Jan 22;2(2):100070. doi: 10.1016/j.bneo.2025.100070. eCollection 2025 May.
6
Protocol: what are the ethnic inequities in care outcomes related to haematological malignancies, treated with transplant/cellular therapies, in the UK? A systematic review.
BMJ Open. 2025 May 21;15(5):e099354. doi: 10.1136/bmjopen-2025-099354.
7
Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.
Curr Oncol. 2025 Mar 31;32(4):204. doi: 10.3390/curroncol32040204.
8
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.
Blood Cancer Discov. 2025 Mar 4;6(2):79-93. doi: 10.1158/2643-3230.BCD-24-0153.
9
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Blood Adv. 2025 Feb 11;9(3):533-544. doi: 10.1182/bloodadvances.2024014127.
10
Reparations for African Enslavement in the U.S. and Black Survival Using the Panel Study of Income Dynamics.
Am J Epidemiol. 2024 Nov 29. doi: 10.1093/aje/kwae444.
本文引用的文献
1
Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
Blood. 2017 Apr 6;129(14):1919-1926. doi: 10.1182/blood-2016-07-726893. Epub 2017 Feb 2.
2
Racial disparities in treatment use for multiple myeloma.
Cancer. 2017 May 1;123(9):1590-1596. doi: 10.1002/cncr.30526. Epub 2017 Jan 13.
3
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.
Cancer Control. 2016 Oct;23(4):327-337. doi: 10.1177/107327481602300404.
5
Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
Cancer. 2016 Sep 1;122(17):2723-30. doi: 10.1002/cncr.30089. Epub 2016 Jun 10.
6
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.
Leuk Lymphoma. 2016 Dec;57(12):2827-2832. doi: 10.3109/10428194.2016.1170828. Epub 2016 Apr 22.
7
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):350-7. doi: 10.1016/j.clml.2016.02.036. Epub 2016 Mar 8.
8
Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study.
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):264-73. doi: 10.1158/1055-9965.EPI-15-0756. Epub 2016 Jan 29.
9
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
10
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
Zotero 插件